Levee Medical Strengthens Innovation with New U.S. Patent
Levee Medical, a dedicated medical device company, has made significant strides in enhancing outcomes for patients undergoing prostate cancer surgery. The firm recently celebrated a major milestone with the issuance of a foundational patent by the United States Patent and Trademark Office. This new patent underscores the company’s commitment to developing effective solutions, ensuring robust protections for its innovative products.
Strengthening Intellectual Property
The newly issued U.S. Patent No. 12,324,586 provides extensive coverage for Levee Medical's Voro Urologic Scaffold, a device specifically designed for Prostatic Urethra Restoration (PUR) to help address stress urinary incontinence. With this patent in place, Levee Medical now holds four issued patents and boasts twelve additional pending applications across major international markets, such as the United States, the European Union, China, and Japan. This strong intellectual property foundation ensures long-term strategic advantages within the urologic device market.
Leadership Comments on Impact
Bruce Choi, the Founder, Director, CTO, and Chairman of Levee Medical, expressed his enthusiasm regarding the patent issuance. He stated, "This new patent is a defining moment for Levee. It provides robust protection for our unique technology and intraoperative placement of the Voro device, which plays a crucial role in aiding the bladder neck and restoring urethral length. These anatomical considerations are vital for quicker recovery of continence after prostate surgery, establishing our leadership in the area of Prostatic Urethra Restoration. This patent quickens our path to offer a groundbreaking solution for patients."
ARID II Trial Shows Promising Progress
Levee Medical is currently focused on the continued advancement of the ARID II trial, a crucial multicenter, randomized, controlled pivotal study assessing the safety and effectiveness of the Voro Urologic Scaffold in men undergoing robotic-assisted radical prostatectomy. The company has recently welcomed Johns Hopkins Medicine as a partner in this study. Dr. Arvin George has taken on the role of national Principal Investigator, bringing excitement and strong leadership to the project.
Involvement from Investigators and Institutions
Investigator enthusiasm surrounding the ARID II IDE pivotal study has been strong. Dr. George noted, "Site activations are progressing successfully, with more to follow. The early enrollment momentum highlights the clinical interest in methods that can improve continence recovery after prostatectomy. Insights from the ARID II trial will not only work towards reducing incontinence rates but also provide valuable information regarding the recovery of urinary control following prostate cancer surgery."
About Levee Medical
Levee Medical is dedicated to creating innovative solutions geared towards minimizing complications linked to surgical treatments for prostate cancer. The Voro Urologic Scaffold is set to be the flagship product that the company intends to launch. As it stands, this device is limited to investigational use and is not yet approved for commercial distribution in the United States or any other region.
Frequently Asked Questions
What is the significance of the new patent?
The new patent protects Levee Medical's innovative Voro Urologic Scaffold technology, strengthening its position in the market.
What does the Voro Urologic Scaffold do?
The Voro Urologic Scaffold is designed to assist in Prostatic Urethra Restoration to mitigate stress urinary incontinence post-surgery.
What is the ARID II trial?
The ARID II trial is a pivotal study assessing the safety and effectiveness of the Voro Urologic Scaffold in men undergoing robotic-assisted prostate surgery.
Who is involved in the ARID II trial?
The trial involves multiple centers, with Dr. Arvin George from Johns Hopkins Medicine serving as the national Principal Investigator.
What is the future outlook for Levee Medical?
With a strong patent portfolio and ongoing clinical trials, Levee Medical is poised for significant advancements in urologic surgical technology.
